Respiratory Syncytial Virus

A single intranasal formulation demonstrated protection against SARS-CoV-2, bacterial pneumonia, and allergens for up to 3 months in preclinical models.

RSV vaccines cut hospitalization risk—and may lower dementia risk.

Thrifty White’s experiences provide practical lessons from designing, training, and standardizing a full-system model.

Pharmacists boost late-season flu, COVID-19, and RSV vaccination with coadministration guidance, fatigue-fighting messaging, and community access strategies.

Research reveals that adults who were hospitalized with RSV experience significant long-term health issues, impacting quality of life and physical function.

Examining Trends From Past Respiratory Virus Seasons Can Inform New Vaccination Strategies

New RSV vaccines for older adults enhance prevention efforts, yet awareness and uptake remain low. Pharmacists play a crucial role in improving vaccination rates.

New research reveals similar severe outcomes for adults hospitalized with hMPV and RSV, emphasizing the need for awareness of both infections.

Multiplex respiratory virus testing enhances clinical decision-making for RSV in community hospitals.

Low RSV vaccination rates among older adults in the US highlight missed opportunities for reducing hospitalizations and health care costs.

Older adults face heightened risks from RSV due to declining immunity and chronic conditions, making vaccination crucial for prevention and health.

A recent study highlights the AOV dual-chamber system as a faster, safer option for RSV vaccine reconstitution, enhancing efficiency for health care providers.

RSV vaccination shows promise in reducing cardiorespiratory hospitalizations among older adults, highlighting potential heart and lung health benefits.

A single dose of an RSV vaccine significantly reduces hospitalization risk for older adults, offering protection for 2 seasons against severe infections.

Vaccination is vital for adults with heart disease to prevent severe respiratory illnesses like RSV, influenza, and COVID-19, enhancing overall health outcomes.

RSV causes a significant burden of acute respiratory infections in older adults.

RSVpreF was well tolerated in nonpregnant and pregnant individuals aged 18 years and older.

RSV vaccination rates among older adults remain low despite new vaccines, highlighting disparities in uptake and the need for targeted outreach.

RSV poses a serious risk to older adults in long-term care, highlighting the need for effective outbreak management and infection control strategies.

RSV hospitalization in older adults links to increased cardiovascular events, highlighting the need for vigilant monitoring and vaccination strategies.

RSV outbreaks pose significant risks globally, highlighting the urgent need for targeted vaccination and treatment strategies to protect vulnerable populations.

Immunocompromised patients, especially transplant recipients, face heightened RSV risks, leading to severe infections and complications.

Researchers unveil compounds that enhance cell death and boost antiviral responses, offering hope against RSV and other viral infections.